greeksoup/ stock research

Strata Critical Medical (SRTA) Q1 FY2026 earnings: revenue $67 million, up 87.4% on the year

Strata Critical Medical, Inc. (SRTA) reported revenue of $67 million for Q1 FY2026, the quarter ended 31 March 2026, up 87.4% on the same quarter a year earlier. Net income was $2 million, and diluted earnings per share $0.03. The figures are the company's own, from the 10-Q it filed with the SEC on 6 May 2026.

Revenue$67 millionup 87.4%
Net income$2 million
Diluted EPS$0.03
QuarterQ1 FY2026ended 31 March 2026

The quarter, against the one before and a year earlier

LineQ1 FY2026Q4 FY2025Q1 FY2025Change on the year
Revenue67.4n/a35.9+87.4%
Cost of revenue53.3n/a28.9+84.3%
Gross profit14.1n/a7.1+100.2%
Gross margin21.0%n/a19.6%
Selling, general and administrative15.6n/a12.3+26.6%
Operating income-3.0n/a-5.7n/a
Operating margin-4.4%n/a-15.8%
Pre-tax income2.4n/a-1.6n/a
Income tax0.0n/a0.0n/a
Effective tax rate0.0%n/an/a
Net income2.2n/a-3.5n/a
Net margin3.2%n/a-9.7%
Diluted EPS$0.03n/a-$0.04n/a
$ million except per share.
Read moreFourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed.

Cash flow and capital returned

LineQ1 FY2026Q4 FY2025Q1 FY2025Change on the year
Operating cash flow3.9n/a-0.2n/a
Capital expenditure5.2n/a2.6+97.7%
Free cash flow-1.3n/a-2.9n/a
Free cash flow margin-1.9%n/a-8.0%
Cash from investing24.7n/a20.4+21.2%
Cash from financing-0.9n/a-4.2n/a
Depreciation and amortisation3.1n/a1.7+80.3%
Share-based compensation5.0n/a4.2+19.4%
Diluted shares, weighted90m82m80m+12.9%
Shares outstanding at period end87m87m81m+6.8%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ1 FY2026Q4 FY2025Q1 FY2025Change on the year
Shareholders' equity286279220+30.0%
Debt0.00.00.0n/a
Operating lease liabilities3.52.75.7-39.0%
Other liabilities38.443.725.1+52.9%
Total liabilities and equity328325251+30.8%
Fixed assets40.136.432.6+23.1%
Goodwill88.688.242.0+110.7%
Intangible assets46.347.513.5+242.3%
Investments0.130.385.2-99.9%
Cash and equivalents58.731.034.8+68.6%
Receivables39.640.022.1+79.0%
Other assets54.252.120.3+167.4%
Total assets328325251+30.8%

Questions

What was Strata Critical Medical's revenue in Q1 FY2026?

Strata Critical Medical (SRTA) reported revenue of $67 million for Q1 FY2026, the quarter ended 31 March 2026, up 87.4% on the same quarter a year earlier.

How much did Strata Critical Medical earn in Q1 FY2026?

Net income for Q1 FY2026 was $2 million, and diluted earnings per share $0.03.

When did Strata Critical Medical report Q1 FY2026 results?

Strata Critical Medical filed its 10-Q for the quarter ended 31 March 2026 with the SEC on 6 May 2026.

Quarterly results, the last 20 quarters

Q3 FY2021Q4 FY2021Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024 †Q4 FY2024 *Q1 FY2025 †Q2 FY2025 †Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026
Revenue20.324.626.635.645.738.145.361.071.447.551.567.936.154.435.945.149.3n/a67.472.5
Cost of revenue15.920.623.730.536.533.238.150.655.938.541.451.628.641.828.936.137.7n/a53.357.3
Gross profit4.54.02.95.19.35.07.210.415.69.010.116.47.512.67.19.011.6n/a14.115.2
Gross margin22%16%11%14%20%13%16%17%22%19%20%24%21%23%20%20%24%n/a21%21%
SG&An/an/an/an/an/an/an/an/an/an/an/an/an/an/a12.313.3n/an/a15.614.0
Operating income-9.7-10.5-13.7-9.7-10.4-19.7-12.8-12.2-7.4-35.6-9.9-12.1-7.1-8.4-5.7-4.6-5.6n/a-3.0-5.4
Operating margin-48%-43%-51%-27%-23%-52%-28%-20%-10%-75%-19%-18%-20%-15%-16%-10%-11%n/a-4%-7%
Pre-tax income-12.80.7-11.08.4-9.2-16.2-10.4-12.60.4-35.0-4.3-11.3-5.6-9.9-1.6-3.4-9.7n/a2.4-10.5
Tax raten/a-16%n/a0%n/an/an/an/a31%n/an/an/an/an/an/an/an/an/a0%n/a
Net income-9.20.8-11.08.4-9.2-15.4-10.2-12.20.3-33.9-4.2-11.3-2.0-9.8-3.5-3.757.4n/a2.2-10.5
Net margin-45%3%-41%24%-20%-40%-23%-20%0%-71%-8%-17%-5%-18%-10%-8%116%n/a3%-15%
Diluted EPS-$0.13$0.01-$0.16$0.10-$0.13n/a-$0.14-$0.17$0.00-$0.45-$0.06-$0.15-$0.03-$0.11-$0.04-$0.05$0.70n/a$0.03-$0.12
Operating cash flow-5.8-6.0-10.1-11.6-6.4-9.1-16.9-8.22.0-9.3-15.68.46.4-1.8-0.2-3.1-37.3n/a3.95.7
Capital expenditure0.1n/a0.40.20.10.00.60.70.70.00.816.29.34.62.62.32.8n/a5.22.5
Free cash flow-5.9n/a-10.5-11.8-6.4-9.1-17.5-8.91.3-9.3-16.4-7.7-3.0-6.3-2.9-5.4-40.1n/a-1.33.2
Buybacksn/an/an/an/an/an/an/an/a0.0n/an/an/a0.0n/an/an/a0.0n/an/an/a
Shares outstanding72m71m71m71m72m72m73m74m75m75m77m78m78m80m81m82m86m87m87m88m
Filing10-Q10-QT10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter left blank is one the arithmetic cannot give yet: the annual report changed the basis of the year (a business sold or spun off, a line regrouped), so the year less the three quarters as first filed would not be a quarter of anything. It fills in once the three quarters have been refiled on the new basis. A blank figure marked on a quarter is one the filings do not give on their own: the quarters as filed do not add to the year the company filed, or the year and its quarters stand on different share counts. Each quarter's page says which. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 31 March 2026, filed 6 May 2026: the filing.